Wells Fargo’s ProQR Therapeutics PRQR Stock Holding History

Wells Fargo’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.48K	Hold	4,000	–	–	﹤0.01%	6057
2025 Q4	$8.08K	Sell	4,000 -1,610	-29%	-$3.76K	﹤0.01%	5995
2025 Q3	$11.9K	Hold	5,610	–	–	﹤0.01%	5912
2025 Q2	$11.4K	Sell	5,610 -1,000	-15%	-$1.63K	﹤0.01%	5917
2025 Q1	$8.79K	Sell	6,610 -2,145	-25%	-$4.57K	﹤0.01%	5912
2024 Q4	$23.2K	Sell	8,755 -471	-5%	-$1.5K	﹤0.01%	5731
2024 Q3	$16.8K	Sell	9,226 -1,770	-16%	-$3.32K	﹤0.01%	5686
2024 Q2	$18.3K	Hold	10,996	–	–	﹤0.01%	5613
2024 Q1	$25.2K	Hold	10,996	–	–	﹤0.01%	5506
2023 Q4	$21.8K	Hold	10,996	–	–	﹤0.01%	5610
2023 Q3	$14.3K	Hold	10,996	–	–	﹤0.01%	5714
2023 Q2	$17.8K	Hold	10,996	–	–	﹤0.01%	5776
2023 Q1	$23.4K	Hold	10,996	–	–	﹤0.01%	5572
2022 Q4	$40.7K	Hold	10,996	–	–	﹤0.01%	4960
2022 Q3	$8K	Hold	10,996	–	–	﹤0.01%	5774
2022 Q2	$9K	Hold	10,996	–	–	﹤0.01%	5801
2022 Q1	$10K	Hold	10,996	–	–	﹤0.01%	6272
2021 Q4	$88K	Hold	10,996	–	–	﹤0.01%	5710
2021 Q3	$92K	Hold	10,996	–	–	﹤0.01%	5421
2021 Q2	$74K	Hold	10,996	–	–	﹤0.01%	5408
2021 Q1	$73K	Hold	10,996	–	–	﹤0.01%	5630
2020 Q4	$46K	Hold	10,996	–	–	﹤0.01%	5607
2020 Q3	$53K	Sell	10,996 -1,000	-8%	-$5.23K	﹤0.01%	5488
2020 Q2	$73K	Hold	11,996	–	–	﹤0.01%	5361
2020 Q1	$65K	Hold	11,996	–	–	﹤0.01%	5253
2019 Q4	$119K	Buy	11,996 +1,000	+9%	+$7.79K	﹤0.01%	5216
2019 Q3	$63K	Hold	10,996	–	–	﹤0.01%	5492
2019 Q2	$100K	Hold	10,996	–	–	﹤0.01%	5313
2019 Q1	$153K	Hold	10,996	–	–	﹤0.01%	4950
2018 Q4	$174K	Sell	10,996 -830	-7%	-$15.2K	﹤0.01%	5005
2018 Q3	$229K	Sell	11,826 -2,000	-14%	-$21.3K	﹤0.01%	4938
2018 Q2	$101K	Sell	13,826 -23,800	-63%	-$120K	﹤0.01%	5376
2018 Q1	$116K	Hold	37,626	–	–	﹤0.01%	5246
2017 Q4	$122K	Sell	37,626 -5,600	-13%	-$20.1K	﹤0.01%	5223
2017 Q3	$210K	Buy	43,226 +29,400	+213%	+$153K	﹤0.01%	4903
2017 Q2	$72K	Buy	13,826 +3,000	+28%	+$14.9K	﹤0.01%	5294
2017 Q1	$54K	Hold	10,826	–	–	﹤0.01%	5419
2016 Q4	$53K	Sell	10,826 -180	-2%	-$927	﹤0.01%	5359
2016 Q3	$73K	Buy	11,006 +2,935	+36%	+$16.2K	﹤0.01%	5102
2016 Q2	$39K	Sell	8,071 -2,500	-24%	-$12.9K	﹤0.01%	5292
2016 Q1	$52K	Buy	10,571 +7,116	+206%	+$36.2K	﹤0.01%	5213
2015 Q4	$30K	Buy	3,455 +955	+38%	+$11K	﹤0.01%	5466
2015 Q3	$36K	Buy	2,500 +1,000	+67%	+$16.7K	﹤0.01%	5368
2015 Q2	$25K	Buy	+1,500	New	+$28.3K	﹤0.01%	5531

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Wells Fargo's PRQR Position: Q1 2026 in Review

Wells Fargo held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 4,000 shares worth $6.48K. The position accounts for ﹤0.01% of the portfolio, ranked #6057.

Wells Fargo first reported a position in PRQR in Q2 2015 and has held it in 44 quarters since. The position peaked at $229K in Q3 2018. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Wells Fargo held 4,000 shares of ProQR Therapeutics worth $6.48K as of Q1 2026.
Wells Fargo left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6057 holding.
Wells Fargo first reported a position in ProQR Therapeutics in Q2 2015 and has held it in 44 quarters since.
Wells Fargo's ProQR Therapeutics position peaked at $229K in Q3 2018.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.